The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Octreotide Therapy of Pediatric Hypothalamic Obesity: A Double-Blind, Placebo-Controlled Trial
Abstract
Hypothalamic obesity is a devastating complication in children surviving brain tumors and/or cranial irradiation. These subjects are thought to exhibit autonomic dysregulation of the beta-cell, with insulin hypersecretion in response to oral glucose tolerance testing (OGTT). We report the results of a randomized, double-blind, placebo-controlled trial of octreotide therapy for pediatric hypothalamic obesity. Eighteen subjects [weight, 100.6 +/- 5.6 kg; body mass index (BMI), 37.1 +/- 1.3 kg/m(2)] received octreotide (5-15 microg/kg x d s.c.) or placebo for 6 months. With octreotide, Delta weight (mean +/- SEM) was +1.6 +/- 0.6 vs. +9.1 +/- 1.7 kg for placebo (P < 0.001). Delta BMI was -0.2 +/- 0.2 vs. +2.2 +/- 0.5 kg/m(2), respectively (P < 0.001). OGTT documented Delta insulin response (peak - basal) of -417 +/- 304 pM after octreotide vs. +216 +/- 215 pM after placebo (P = 0.034). Improvement in physical activity by parent report was noted with octreotide, but not placebo (P = 0.03). For the octreotide group, changes in quality of life positively correlated with changes in insulin response (P = 0.041). Complications and adverse events were mild and self-limited. These data demonstrate the beneficial effects of octreotide in pediatric hypothalamic obesity. Octreotide suppressed insulin, and stabilized weight and BMI. Improved quality of life correlated with the degree of insulin suppression. Octreotide was safe and well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351
Hypothalamic and genetic obesity in experimental animals: an autonomic and endocrine hypothesis
Bray, G. A., & York, D. A. (1979) · Physiological Reviews · doi:10.1152/physrev.1979.59.3.719 · Cited by 1,132
Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity
Vaisse, C., Clement, K., Durand, E., Hercberg, S., Guy-Grand, B., & Froguel, P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9238 · Cited by 897
BERTHOUD, H. R., & JEANRENAUD, B. (1979) · Endocrinology · doi:10.1210/endo-105-1-146 · Cited by 266 · cited 1×
“First, acetylcholine binds to the M3 muscarinic receptor on the -cell, opening a sodium channel, which augments depolarization (38), and leads to a widening of the voltage-gated calcium channel, and insulin vesicular exocytosis (33, 39, 40).”
BackgroundRohner-Jeanrenaud, F., & Jeanrenaud, B. (1980) · Journal of Clinical Investigation · doi:10.1172/jci109744 · Cited by 80
Cited by
Insulin Resistance and Hyperinsulinemia
Shanik, M. H., Xu, Y., Škrha, J., Dankner, R., Zick, Y., & Roth, J. (2008) · Diabetes Care · doi:10.2337/dc08-s264 · Cited by 791
Current and investigational antiobesity agents and obesity therapeutic treatment targets
Bays, H. E. (2004) · Obesity Research · doi:10.1038/oby.2004.151 · Cited by 228
Hyperinsulinemia: A cause of obesity?
Erion, K. A., & Corkey, B. E. (2017) · Current Obesity Reports · doi:10.1007/s13679-017-0261-z · Cited by 161
van Iersel, L., Brokke, K. E., Adan, R. A. H., Bulthuis, L. C. M., van den Akker, E. L. T., & van Santen, H. M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00017 · Cited by 146
Müller, H. L., Tauber, M., Lawson, E. A., Özyurt, J., Bison, B., Martinez-Barbera, J.-P., Puget, S., Merchant, T. E., & van Santen, H. M. (2022) · Nature Reviews Disease Primers · doi:10.1038/s41572-022-00351-z · Cited by 144
Semiquantitative analysis of hypothalamic damage on MRI predicts risk for hypothalamic obesity
Roth, C. L., Eslamy, H., Werny, D., Elfers, C., Shaffer, M. L., Pihoker, C., Ojemann, J., & Dobyns, W. B. (2015) · Obesity · doi:10.1002/oby.21067 · Cited by 96
Roth, C. L., Perez, F. A., Whitlock, K. B., Elfers, C., Yanovski, J. A., Shoemaker, A. H., & Abuzzahab, M. J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14224 · Cited by 87
Roth, C. L., Scimia, C., Shoemaker, A. H., Gottschalk, M., Miller, J., Yuan, G., Malhotra, S., & Abuzzahab, M. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00087-1 · Cited by 76
Hypothalamic obesity: prologue and promise
Abuzzahab, M. J., Roth, C. L., & Shoemaker, A. H. (2019) · Hormone Research in Paediatrics · doi:10.1159/000496564 · Cited by 71
Acquired hypothalamic obesity: A clinical overview and update
Roth, C. L., & McCormack, S. E. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15530 · Cited by 42
Brauner, R., Serreau, R., Souberbielle, J.-C., Pouillot, M., Grouazel, S., Recasens, C., Zerah, M., Sainte-Rose, C., & Treluyer, J.-M. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2126 · Cited by 37
A Novel Rodent Model That Mimics the Metabolic Sequelae of Obese Craniopharyngioma Patients
Roth, C. L., Blevins, J. E., Ralston, M., Elfers, C., Ogimoto, K., Kaiyala, K. J., & Morton, G. J. (2011) · Pediatric Research · doi:10.1203/pdr.0b013e3182083b67 · Cited by 35
van Santen, H. M., Schouten-Meeteren, A. Y., Serlie, M., Meijneke, R. W. H., van Trotsenburg, A. S., Verberne, H., Holleman, F., & Fliers, E. (2015) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2014-0337 · Cited by 32
Perez, F. A., Elfers, C., Yanovski, J. A., Shoemaker, A. H., Abuzzahab, M. J., & Roth, C. L. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14366 · Cited by 29
Semaglutide treatment of hypothalamic obesity – a real-life data study
Svendstrup, M., Rasmussen, A. K., Kistorp, C., Klose, M., & Andreassen, M. (2024) · Pituitary · doi:10.1007/s11102-024-01429-5 · Cited by 23
van Santen, H. M., & Müller, H. L. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf025 · Cited by 21
Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity
Horne, V. E., Bielamowicz, K., Nguyen, J., Hilsenbeck, S., Lindsay, H., Sonabend, R., Wood, A. C., Okcu, F., & Sisley, S. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28379 · Cited by 20
Suppression of insulin secretion in the treatment of obesity: a systematic review and meta-analysis
Huang, Z., Wang, W., Huang, L., Guo, L., & Chen, C. (2020) · Obesity · doi:10.1002/oby.22955 · Cited by 13
Multidisciplinary Approach for Hypothalamic Obesity in Children and Adolescents: A Preliminary Study
Tessaris, D., Matarazzo, P., Tuli, G., Tuscano, A., Rabbone, I., Spinardi, A., Lezo, A., Fenocchio, G., Buganza, R., & de Sanctis, L. (2021) · Children · doi:10.3390/children8070531 · Cited by 11
Jung, H. W., Kim, H. Y., Kim, J. Y., Cheon, J.-E., Kim, I.-O., Kim, S.-K., Shin, C. H., Yang, S. W., & Lee, Y. A. (2021) · PLOS ONE · doi:10.1371/journal.pone.0246789 · Cited by 5
Metadata
- Authors
- Lustig, R. H., Hinds, P. S., Ringwald-Smith, K., Christensen, R. K., Kaste, S. C., Schreiber, R. E., Rai, S. N., Lensing, S. Y., Wu, S., & Xiong, X.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-06
- Volume
- 88
- Issue
- 6
- Pages
- 2586-2592
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2000637330
- Cited by
- 299
- References
- 5
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
